Dosing Tacrolimus Based on CYP3A5 Genotype: Will It Improve Clinical Outcome?

Research output: Contribution to journalArticleAcademicpeer-review

33 Citations (Scopus)


Tacrolimus, widely used to prevent acute rejection following solid-organ transplantation, has become the cornerstone of immunosuppressive therapy after kidney transplantation. More than 70% of all renal transplant recipients receive this remarkably effective agent.(1) But tacrolimus is also highly toxic, and there is great between-patient variability in its pharmacokinetics. This, combined with a low therapeutic index, mandates routine therapeutic drug monitoring in clinical practice.(2) Typically, predose concentrations are monitored and the dose is adjusted to aim for target values that depend on immunological risk, comedication, and time since transplantation.(2)
Original languageUndefined/Unknown
Pages (from-to)640-641
Number of pages2
JournalClinical Pharmacology & Therapeutics
Issue number6
Publication statusPublished - 2010

Research programs

  • EMC MM-04-39-05
  • EMC OR-01-34-01

Cite this